AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The stock is down 7.03% year-to-date as of mid-April 2026, sitting at $208.99, and it represents a level some analysts view as an opportunity. Here are three reasons the bull case remains compelling.
Reason 1: The Dividend Machine Keeps Paying Investors to Wait
AbbVie is a Dividend King with a proven track record. The quarterly dividend has risen every year since the company’s 2013 spin-off from Abbott Laboratories, climbing from $0.40 per quarter in 2013 to $1.73 per quarter today.
That most recent raise, announced in Q3 2025, was a 5.5% increase from $1.64. The annual dividend now stands at $6.65 per share, delivering a 3.19% yield at current prices. AbbVie pays shareholders every quarter without fail.
Reason 2: Skyrizi and Rinvoq Are Replacing Humira Faster Than Expected
The bear case on AbbVie for years was simple: Humira goes off patent, the company craters. That story is dead. AbbVie posted record net sales in just the second full year following the U.S. Humira loss of exclusivity, with full-year 2025 revenue reaching $61.16 billion, up 8.57% year-over-year.
Skyrizi generated $5 billion in Q4 2025 alone, up 32.5% year-over-year, and Rinvoq added $2.37 billion in Q4, up 29.5%. Rinvoq now carries 9 U.S. approved indications, with a pending filing for vitiligo that could make it the first systemic treatment for that condition.
Humira fell 25.9% in Q4 2025 to $1.24 billion, but that erosion is managed and predictable, offset by the next-generation franchise. The immunology segment grew 18.3% in Q4 to $8.62 billion overall. The replacement is working.
Reason 3: The Forward Valuation Underprices This Growth
The trailing P/E looks elevated at 88x, but that’s distorted by massive acquired In Process Research & Development charges totaling $5 billion pre-tax for full-year 2025, explicitly excluded from forward guidance. Strip those out: management guided for adjusted diluted EPS of $14.37 to $14.57 in 2026, up from $10 in full-year 2025.
That puts the forward P/E at roughly 14x at current prices, for a business growing adjusted earnings at a pace the guidance midpoint implies is nearly 45%.
The PEG ratio confirms the disconnect: 0.476. Wall Street agrees, with the analyst consensus price target at $249 against a current price of $208.99, and 22 analysts rated buy or strong buy versus zero sells.
What Could Go Wrong
The real risk is Humira’s decline accelerating beyond what Skyrizi and Rinvoq can absorb, and pipeline bets on obesity (via the Gubra partnership for ABBV-295) and new oncology approvals taking longer or costing more than expected.
But AbbVie’s $100 billion U.S. R&D and capital investment commitment over the next decade, three-year tariff and pricing mandate exemptions secured through its voluntary agreement with the Trump administration, and a neuroscience segment that grew 17.9% in Q4 to $2.961 billion tell me the platform is diversified enough to absorb setbacks.
With Q1 2026 earnings confirmed for April 29, 2026, the next data point arrives in less than two weeks. The forward earnings acceleration, unbroken dividend growth streak, and underpriced pipeline present a case that warrants close attention from investors evaluating the stock.
Top Gaining Stocks
Top Losing Stocks